718610-25-4

Basic information

• Product Name: (R) 3-(1-methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde
• Synonyms: (R) 3-(1-methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde
• CAS NO: 718610-25-4
• Molecular Weight: 331.384
• Mol File: 718610-25-4.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: (R) 3-(1-methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: (R) 3-(1-methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde(718610-25-4)
• EPA Substance Registry System: (R) 3-(1-methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde(718610-25-4)

Safety Data

• Hazardous Substances Data: 718610-25-4(Hazardous Substances Data)

Upstream product

• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 527693-82-9 3-[N-(benzyloxycarbonylpiperidin-4-yl)]propenoic acid 
• 156545-07-2 3,5-difluorophenylboronic acid 
• 718610-71-0 (R)-3-[N-(benzyloxycarbonyl)piperidin-4-yl]-3-(3,5-difluorophenyl)propanoic acid isopropyl ester 
• 718610-73-2 (R)-iso-propyl 3-(3,5-difluorophenyl)-3-(1-(methylsulfonyl)piperidine-4-yl)propanoate 
• 868669-87-8 (4S,5R)-1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propanoyl}-3,4-dimethyl-5-phenylimidazolidin-2-one 
• 718610-76-5 1-[3-(N-methanesulphonylpiperidin-4-yl)propenyl]-(4S,SR)-3,4-dimethyl-4-phenyl-imidazolidin-2-one 
• 833491-33-1 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid 
• 718610-74-3 (3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propan-1-ol 

Downstream Products

• 718610-24-3 (R) N-(3-[3,5-difluorophenyl]-3-[1-methanesulphonylpiperidin-4-yl]propyl)-4-[2-(4-methanesulphonylphenylsulphonyl)-ethyl]piperidine 
• 835876-97-6 tert-butyl [(1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)-piperidin-4-yl]propyl}piperidin-4-yl)methyl]carbamate 
• 895541-47-6 1-{(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulphonyl)phenyl]propyl}-N-ethylpiperidin-4-amine 
• 835876-98-7 1-(1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidin-4-yl)methanamine 
• 1030849-67-2 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine 
• 1030849-66-1 4-{(1R,3S)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine 
• 1031207-73-4 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine 
• 1031207-75-6 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1S,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine 
• 895541-78-3 tert-butyl (cyclopropylmethyl)(1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidin-4-yl)carbamate 
• 872879-86-2 [3H]-AZD₅₆₇₂ 
• 895541-80-7 tert-butyl (1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidin-4-yl)methylcarbamate 
• 835876-99-8 tert-butyl [2-(1-{(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)-phenyl]propyl}piperidin-4-yl)ethyl]carbamate 

Relevant articles and documents

Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis

Modifications to a series of potent and selective substituted 1-(3,3-diphenylpropyl)-piperidine phenylacetamide CCR5 antagonists were explored with the aim of reducing affinity at the hERG cardiac ion channel. Replacement of one aromatic ring in the diphe

Chemical Compound

The present invention relates to 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine (I): or a pharmaceutically acceptable salt thereof, as well as to processes for preparing

CHEMICAL COMPOUNDS

Compounds of formula (I): wherein: when X is NR5, Y is absent or is CH2; when X is CH2, Y is absent, CH2, NR6, O, S, S(O) or S(O)2; Z is a 5- or 6-membered heterocyclyl ring; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).